Skip to content

Study · Not a test of the peptide alone · 2024

2 results

Association between renal function and fracture incidence during treatment with teriparatide or alendronate: an exploratory subgroup analysis of the Japanese Osteoporosis Intervention Trial-05.

Takeuchi Y, Tanaka S, Kuroda T, Hagino H, Mori S, Soen S

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA30 Sept 2024Cited by 6 (Europe PMC)

PMID39343826 (opens in a new tab)PMCIDPMC11579086 (opens in a new tab)DOI10.1007/s00198-024-07260-9 (opens in a new tab)PepBankPUB-39343826
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In elderly women with CKD 1/2, sequential teriparatide-alendronate reduced vertebral fracture incidence versus alendronate alone.

    In plain wordsIn elderly women with CKD 1/2, sequential teriparatide-alendronate reduced spinal fractures versus alendronate alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVertebral fractures in CKD 1/2
    Study

    n = 556

    Comparator
    Alendronate monotherapy
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In CKD 1/2 patients (N = 556 with 90 incidents of morphometric vertebral fracture), the incidence of vertebral fractures was lower in the TPTD-ALN group than in the ALN group (p = 0.01).
    2 context sentences
    Summary · context
    This is an exploratory subgroup analysis according to chronic kidney disease (CKD) status at baseline.
    Summary · context
    Participants received sequential therapy with TPTD for 72 weeks, followed by ALN for 48 weeks (TPTD-ALN group, N = 483) or ALN monotherapy for 120 weeks (ALN group, N = 496).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In elderly women with CKD 3b/4, non-vertebral fractures were more frequent with sequential teriparatide-alendronate than alendronate alone, with few fractures.

    In plain wordsIn elderly women with CKD 3b/4, non-spinal fractures were more frequent with sequential teriparatide-alendronate than alendronate alone, with few fractures.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseNon-vertebral fractures in CKD 3b/4
    Study

    n = 112

    Comparator
    Alendronate monotherapy
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In CKD 3b/4 patients (N = 112 with 10 incidents of non-vertebral fracture), the incidence of non-vertebral fractures was lower in the ALN group than in the TPTD-ALN group, although the number of fractures was small.
    2 context sentences
    Summary · context
    This is an exploratory subgroup analysis according to chronic kidney disease (CKD) status at baseline.
    Summary · context
    Participants received sequential therapy with TPTD for 72 weeks, followed by ALN for 48 weeks (TPTD-ALN group, N = 483) or ALN monotherapy for 120 weeks (ALN group, N = 496).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.